Dear EURETINA Members, A very warm welcome to the September 1st, 2025 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted for an… Read More »September 1st, 2025 “EURETINA-Brief”© Issue No. 324
Researchers at the Centre Hospitalier National d’ophtalmologie des Quinze-Vingts, INSERM, Paris, France, and at the Institut de la Vision, Sorbonne Universités, INSERM, CNRS, Paris, France,… Read More »A concept elicitation study on qualitative interviews for Retinitis pigmentosa (RP) and Choroideremia (CHM).
Researchers at the Biomedical Graduate Program and the Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, USA, have published a systematic review on serious adverse events… Read More »A systematic review of retinal gene therapy on the impact of route administrations and on serious adverse events (SAEs).
Opus Genetics (Nasdaq: IRD) have announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for OPGx-BEST1, a… Read More »A new gene therapy candidate – “OPGxBEST1” – has received FDA clearance from Opus Genetics for an investigational new drug application (IND) for the treatment of bestrophin-1-related IRD.
Dear EURETINA Members, A very warm welcome to the August 15th, 2025 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue… Read More »August 15th, 2025 “EURETINA-Brief”© Issue No. 323
A consortium of researchers from Australia, New Zealand, USA, UK and Switzerland, have published paper for a new treatment outcome and natural history registry for… Read More »An international consortium have presented “THE FIGHT INHERITED RETINAL BLINDNESS! PROJECT” – a new treatment outcome and natural history registry for inherited retinal disease (IRD).
Researchers at the Department of Ophthalmology, Vagelos College of Physicians and Surgeons, Columbia University, New York, have published a study outlining how fundus autofluorescence (FAF)… Read More »A review of fundus autofluorescence (FAF) underscores an indispensable technology for the diagnosis, monitoring and outcome measures of numerous retinal diseases.
4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT), based in Emeryville, California, have announced 60-week summary data from their “SPECTRA” diabetic macular edema (DME) Phase III clinical… Read More »60-week results from 4D-150 “SPECTRA” treatment for DME Phase 3 data reports sustained visual acuity gains.
Dear EURETINA Members, A very warm welcome to the August 4th, 2025 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue… Read More »August 4th, 2025 “EURETINA-Brief”© Issue No. 322
Researchers at the Department of Human Genetics, Radboud University Medical Centre, Nijmegen, the Netherlands, have reported a limited study for three probands showing that biallelic… Read More »A small study of severe variants of ABCA4 reports a new genotype–phenotype correlation with Early-Onset Severe Retinal Dystrophy (EOSRD).
